NCT04212572

Brief Summary

Salivary gland ultrasonography is identified as a valuable diagnostic tool and potential criteria item for disease classification of sjögren's syndrome and evaluate evolution of parenchyma. The investigators have to include 242 patients. The objective is to evaluate the modification of ultrasonographic abnormalities according to disease in primary Sjögren syndrome.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
242

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2019

Shorter than P25 for all trials

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 20, 2019

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

December 19, 2019

Completed
8 days until next milestone

First Posted

Study publicly available on registry

December 27, 2019

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 20, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 20, 2020

Completed
Last Updated

December 27, 2019

Status Verified

December 1, 2019

Enrollment Period

6 months

First QC Date

December 19, 2019

Last Update Submit

December 26, 2019

Conditions

Keywords

Primary sjögren's syndromeultrasonographysalivary glandsauto-immune disease

Outcome Measures

Primary Outcomes (1)

  • Presence or absence of parenchymal abdnormalities.

    Presence or absence of parenchymal abdnormalities. Scored following a standardized fill and according to disease duration

    inclusion

Secondary Outcomes (1)

  • Parenchymal abnormalities according to disease activity

    inclusion

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with Primary sjögren syndrome

You may qualify if:

  • Male or female patient ≥ 18 years
  • Primary sjögren syndrome according of age to 2002 or 2016 classification criteria

You may not qualify if:

  • Secondary sjögren syndrome

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

CHRU de Brest

Brest, 29609, France

RECRUITING

CHU de LILLE

Lille, 59037, France

NOT YET RECRUITING

CHU de MONTEPELLIER

Montpellier, 34295, France

NOT YET RECRUITING

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 19, 2019

First Posted

December 27, 2019

Study Start

November 20, 2019

Primary Completion

May 20, 2020

Study Completion

May 20, 2020

Last Updated

December 27, 2019

Record last verified: 2019-12

Data Sharing

IPD Sharing
Will share

All collected data that underlie results in a publication

Shared Documents
STUDY PROTOCOL
Time Frame
Data will be available beginning one year and ending two years following the publication
Access Criteria
Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.

Locations